Glaukos has unveiled its next generation trabecular micro-bypass technology, the iStent inject W, the latest evolution of Glaukos’ microinvasive glaucoma surgery (MIGS) device. Designed to treat primary open-angle glaucoma by creating a bypass through the trabecular meshwork, it provides a direct channel between the anterior chamber and Schlemm’s canal to lower intraocular pressure and, hopefully, patient reliance on glaucoma medications.
Like its predecessor, the iStent inject W comes with two stents (compared with just one for Glaukos’ first-generation device), to optimise flow and a wider flange at its base to enhance procedural predictability and surgical confidence, said Glaukos. The safety and efficacy are the same as the iStent inject, which it’s replacing, with the new design intended to make it easier for surgeons to implant correctly.
“Its advantages are easy to see. A wide flange at the base of iStent inject W is designed to facilitate seamless implantation, provide observable positioning confirmation and deliver procedural consistency and predictability,” said Glaukos. “The iStent inject W is built on a solid, dependable foundation of proven efficacy and safety in thousands of eyes worldwide (with a) safety profile similar to cataract surgery alone.”
